PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer

Journal of Pathology

Volumn 224, Issue 4, 2011, Pages 564-574

  Paul, Ian ^a   Savage, Kienan I ^a   Blayney, Jaine K ^a   Lamers, Elisabeth ^a   Gately, Kathy ^b   Kerr, Keith ^d   Sheaff, Michael ^c   Arthur, Kenneth ^a   Richard, Derek J ^e   Hamilton, Peter W ^a   James, Jacqueline A ^a   O'Byrne, Kenneth J ^a   Harkin, D Paul ^a   Quinn, Jennifer E ^a   Fennell, Dean A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

apoptosis; BAK; BAX; BRCA1; non small cell lung cancer; PARP inhibitor; predictive biomarker; synthetic lethality

Indexed keywords

BRCA1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PLATINUM; PROTEIN BAK; PROTEIN BAX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LETHALITY; LUNG NON SMALL CELL CANCER; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA DAMAGE; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; POLY(ADP-RIBOSE) POLYMERASES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UBIQUITIN-PROTEIN LIGASES;

EID: 79959986415     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2925     Document Type: Article

References (39)

1. Venkitaraman AR,. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-182. (Pubitemid 34161138)
2. Farmer H, McCabe N, Lord CJ, et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. (Pubitemid 40559006)
3. Bryant HE, Schultz N, Thomas HD, et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917. (Pubitemid 40559005)
4. Fong PC, Boss DS, Yap TA, et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
5. Catalogue of somatic mutations in cancer, 2010; available from:.
6. Turner N, Tutt A, Ashworth A,. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819. (Pubitemid 39331153)
7. Bindra RS, Glazer PM,. Repression of RAD51 gene expression by E2F4//p130 complexes in hypoxia. Oncogene 2006; 26: 2048-2057.
8. Lee MN, Tseng RC, Hsu HS, et al., Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 2007; 13: 832-838.
9. Bindra RS, Gibson SL, Meng A, et al., Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65: 11597-11604. (Pubitemid 41821719)
10. Taron M, Rosell R, Felip E, et al., BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449. (Pubitemid 39377848)
11. Quinn JE, James CR, Stewart GE, et al., BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13: 7413-7420.
12. Reguart N, Cardona AF, Carrasco E, et al., BRCA1: a new genomic marker for non-small-cell lung cancer. Clin Lung Cancer 2008; 9: 331-339.
13. Rosell R, Perez-Roca L, Sanchez JJ, et al., Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4: e5133.
14. Swisher EM, Gonzalez RM, Taniguchi T, et al., Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 2009; 8: 48.
15. Quinn JE, Kennedy RD, Mullan PB, et al., BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228. (Pubitemid 37255167)
16. Drew Y, Mulligan EA, Vong W-T, et al., Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103 (4): 334-46.
17. Audeh MW, Carmichael J, Penson RT, et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
18. Tutt A, Robson M, Garber JE, et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
19. Johnstone RW, Ruefli AA, Lowe SW,. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164. (Pubitemid 34161136)
20. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
21. Wei MC, Zong WX, Cheng EH, et al., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (NY) 2001; 292: 727.
22. Beroukhim R, Mermel CH, Porter D, et al., The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
23. Gorski JJ, James CR, Quinn JE, et al., BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. Breast Cancer Res Treat 2010; 122: 721-731.
24. Crawford N, Chacko AD, Savage KI, et al., Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis 2011; Mar; 16 (3): 311-20.
25. Wilson CA, Ramos L, Villasenor MR, et al., Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999; 21: 236-240. (Pubitemid 29070375)
26. Al-Mulla F, Abdulrahman M, Varadharaj G, et al., BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem 2005; 53: 621-629. (Pubitemid 40593975)
27. Thrall M, Gallion HH, Kryscio R, et al., BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006; 16 (suppl 1): 166-171.
28. Rogakou EP, Pilch DR, Orr AH, et al., DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-5868. (Pubitemid 28124064)
29. Olaussen KA, Dunant A, Fouret P, et al., DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991. (Pubitemid 44343542)
30. Schiller JH, Harrington D, Belani CP, et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98. (Pubitemid 34438899)
31. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
32. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
33. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566. (Pubitemid 47206930)
34. Brose MS, Volpe P, Feldman M, et al., BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000. (Pubitemid 35424092)
35. Cappuzzo F, Bemis L, Varella-Garcia M,. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354: 2619-2621. (Pubitemid 43882374)
36. Stephens P, Hunter C, Bignell G, et al., Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431: 525-526.
37. Beroukhim R, Mermel CH, Porter D, et al., The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
38. Oltersdorf T, Elmore SW, Shoemaker AR, et al., An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
39. Tumorscape copy number alterations across multiple cancer types, 2010; [cited 2010; available from:.